Durability of response to icotrokinra in adults?with moderate-to-severe plaque psoriasis: 1-year results from the phase III, placebo- and active comparator-controlled ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 trials.

已完结 10 由大三发布于 2026/10/28 16:28:58

DOI:10.1093/bjd/ljag264
作者：Linda Stein Gold,?April W Armstrong,?Jennifer Soung,?Ronald B Vender,?álvaro González Cantero,?Matthias Hoffmann,?Scott T Guenthner,?H Chih-Ho Hong,?Dedee F Murrell,?Eingun James Song,?Leon Kircik,?
文献类型：期刊论文
补充材料：只需要正文

Oxford University Press

Abstract：Background: Icotrokinra, a targeted oral peptide, precisely blocks the interleukin-23 receptor. In two phase III moderate-to--severe plaque psoriasis trials, ICONIC-ADVANCE 1 (NCT06143878) a

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:其它数据库Essential mathemmatical biology.